GENFIT Announces H1 2026 Financial Performance and Strategic Developments

GENFIT, a biopharmaceutical entity, unveiled its financial results for the first half of 2026, reporting revenues of €21.1 million primarily from royalties under the Ipsen agreement. As of June 30, 2026, the company's cash and cash equivalents stood at €113.8 million, projected to fund operations beyond 2028. Operating expenses amounted to €33.8 million, reflecting ongoing R&D activities.

The company highlighted key developments, including Ipsen's increased sales forecast for Iqirvo® in PBC to €1 billion annually. In the U.S., Medicare coverage was secured for the MASH diagnostic NASHnext®, anticipating peak sales over $1.5 billion by 2033. GENFIT is poised to commence Phase 2 trials for nangibotide and nitazoxanide in ACLF by year's end, and continues its GNS561 development in oncology.

Overall, despite a net loss of €26.1 million, GENFIT remains focused on expanding its R&D pipeline, underscoring significant advancements in its therapeutic and diagnostic capabilities.